Collaborations & Alliances

Antios Therapeutics, Assembly Biosciences Enter Clinical Collaboration

Will evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection.

Author Image

By: Charlie Sternberg

Associate Editor

Antios Therapeutics Inc. and Assembly Biosciences Inc. have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection.   A single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial will evaluate ATI-2173, Antios’ investigational proprietary active site polymerase inhibitor nucleotide (ASPIN), vebicorvir (VBR), Assembly Bio’s investigational lead core inhibitor candidate, and tenofo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters